This review highlights the effectiveness of cemiplimab in improving disease outcomes in patients with cutaneous squamous cell carcinoma, indicating significant potential benefits.
Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of cutaneous squamous cell carcinoma (CSCC). Cemiplimab, a human IgG4 monoclonal antibody to the programmed death-1 (PD-1) receptor, has shown impressive response rates and durable disease control in patients with advanced CSCC, alongside a manageable safety profile. More recently, cemiplimab has demonstrated promising efficacy in both the adjuvant and neoadjuvant settings, with impressive improvements in disease-free survival and pathological response rates. This review provides a comprehensive overview of the current role of cemiplimab in the management of CSCC, highlighting key clinical trial data and real-world evidence on its efficacy and safety.
No takes yet. Share an insight, caveat, or question.
McLean et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: